icon-folder.gif   Conference Reports for NATAP  
  16th European AIDS Conference
October 25-27 2017
Milan, Italy
Back grey_arrow_rt.gif
Safety and Efficacy of DTG+RPV in the Phase III SWORD-1 and SWORD-2 Studies: 48 Week Subgroup Analysis by Baseline Third Agent Class and Geographic Location
  Reported by Jules Levin
® 16th European AIDS Conference; October 25-27, 2017; Milan, Italy
C Orkin,1M-A Khuong-Josses,2T Lutz,3D Baker,4R Rubio,5E Blair,6L Kahl,7K Angelis,8M Underwood,6B Wynne,9K Vandermeulen,10M Aboud7
1Barts Health NHS Trust, London, UK;2CHG -Hopital Delafontaine, Saint Denis Cedex, France;3Infektio Research, Frankfurt, Germany;4East Sydney Doctors, Darlinghurst, Sydney, Australia;5Hospital 12 de Octubre, Madrid, Spain;6ViiV Healthcare, Research Triangle Park, NC, USA;7ViiV Healthcare, Brentford, UK;8GlaxoSmithKline, Uxbridge, UK;9ViiV Healthcare, Collegeville, PA, USA;10Janssen, Beerse, Belgium
FDA approves first two-drug regimen for certain patients with HIV - Fixed Dose dolutegravir and rilpivirine - FDA News Release - (11/28/17)
Juluca® (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for themaintenance treatment of virologically suppressed HIV-1 infection - PRESS RELEASE - (11/28/17)
JULUCA (dolutegravir and rilpivirine)FDA Prescribing Information - (12/07/17) 
IAS: Sub-Study 202094 of SWORD-1 and SWORD-2: Switch From TDF-Containing Regimen to DTG + RPV Improves Bone Mineral Density and Bone Turnover Markers Over 48 Weeks- - (07/26/17)
CROI: SWORD 1 & 2: Switch to DTG + RPV Maintains Virologic Suppression Through 48 Weeks, a Phase III Study - (02/16/17)
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine-Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis - (06/20/17)